Interface Bio emerges with $3m to harness the microbiome against inflammation

AI-powered platform identifies bacterial natural products with the potential to modulate the immune system and reduce inflammation.
Biotech startup Interface Biosciences has secured $3 million in an oversubscribed seed funding round to advance its AI drug discovery…Read More

Insilico announces first-in-human study for oral PHD inhibitor for IBD

Biotech aims to accelerate clinical trials to reach unmet clinical needs for inflammatory bowel disease.
Insilico Medicine, a generative AI-driven clinical-stage biotech, has announced it has initiated the first-in-human study for ISM5411, a potentially first-in-class PHD…Read More

Stanford organ aging study spawns new longevity startup

Teal Omics founded after researchers develop algorithm that measures how fast individual organs are aging.
A study led by researchers from Stanford Medicine, published this week in Nature, has unveiled a new method to predict the biological aging rates of individual organs. By analyzing…Read More

EyePoint raises $230 million following positive AMD trial results

Company targets Phase 3 trial in 2024 after wet AMD treatment achieves ‘statistical non-inferiority’ compared with aflibercept in Phase 2.
Retinal health biotech EyePoint Pharmaceuticals (NASDAQ: EYPT) has closed an underwritten public offering of shares of its common stock, rai…Read More

MitoRx raises $5 million to advance mitochondrial dysfunction therapeutics
Author: Danny Sullivan | Published on: December 13, 2023 | Last updated: December 13, 2023

Early data shows company’s lead asset ‘preserves strength in oxidative muscle and confirms mitochondrial modulation.’
British longevity biotech MitoRx Therapeutics has concl…Read More

Encellin pouches $9.9m to target diabetes with cell encapsulation tech
Author: Danny Sullivan | Published on: December 13, 2023 | Last updated: December 13, 2023

Khosla and Y Combinator back UCSF spinout developing implantable pouches that release therapeutic cells when needed.
Biotech startup Encellin has landed a $9.9 million…Read More

More than just a trip – the longevity potential of psychedelics

Terran Biosciences founder on longevity-psychedelic crossovers, targeting neurodegeneration and making history.
Terran Biosciences, a CNS-focused biotech platform company, is developing transformative therapeutics and technologies for patients with neurological and psychiatric d…Read More

‘We’re turning aging research into a therapeutic category’
Rejuvenate Bio CEO on why sourcing gene therapy targets from aging research may hold the key to treating many chronic diseases.
It’s been an interesting year for Harvard spin-out Rejuvenate Bio, which is targeting age-related chronic diseases with gene therapy and cellular reprogr…Read More

UNP lands $32m to advance macrocycle therapeutics for ‘any given target’

Merck and ARTIS Ventures lead round for biotech aiming to ‘bridge the gap between small molecules and biologics.’
Biotech firm Unnatural Products (UNP) has secured $32 million in Series A funding to support the development of its platform that integrates artific…Read More

Swedish biotech lands $4m for non-drug approach to obesity and diabetes

Sigrid Therapeutics deploys micron-sized silica particles to prevent digestive enzymes from breaking down carbohydrates and fats.
Funding continues to flow for companies targeting obesity, with Swedish biotech Sigrid Therapeutics revealing it has raised $4 million in an…Read More